PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

On June 18, 2025, the FDA approved Yeztugo, the brand name for subcutaneous lenacapavir, a prescription medication used for the pre-exposure prophylaxis of HIV. Subcutaneous lenacapavir is administered twice a year (every six months) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at risk. With patients only needing lenacapavir twice a year for HIV prevention, the field has been optimistic about the potential for lenacapavir to reduce barriers and improve access to PrEP. Since we are still early in the rollout subcutaneous lenacapavir, many providers have questions about how to offer it to their patients—from workflow to billing to managing potential side effects and drug-drug interactions.

On this episode, Antonio Urbina, MD, Medical Director for CEI’s HIV Primary Care and Prevention Center of Excellence, speaks with Alex Danforth, PharmD. Alex Danforth is a clinical pharmacist in Rochester, NY. She practices at Trillium Health, a federally qualified health center, where she works with patients and providers to help manage medications and optimize care. Alex currently provides clinical leadership for HIV treatment and prevention programs.

Drs. Urbina and Danforth talk about the latest New York State Clinical Guidelines for PrEP, which were updated on October 16th. The new guidelines provide important updates, including subcutaneous lenacapavir. They discuss important considerations for initiating patients on lenacapavir as well as some early lessons learned from implementing lenacapavir in their Rochester- and New York City-based clinics. Related Content:

Jaksot(62)

We can do it! Improving access to care for transgender and gender diverse patients

We can do it! Improving access to care for transgender and gender diverse patients

Compared with the general population, transgender and gender diverse people are more likely to experience poor health outcomes, such as chronic health conditions, HIV, substance use, and mental illnes...

14 Joulu 202317min

What is Doxy-PEP?  A Conversation about the Use of Doxycycline Post Exposure Prophylaxis to Prevent STIs

What is Doxy-PEP? A Conversation about the Use of Doxycycline Post Exposure Prophylaxis to Prevent STIs

In this episode, Dr. Marguerite Urban and Dr. Daniela DiMarco discuss Doxy-PEP, a new tool for the prevention of bacterial STIs.  Drs. Urban and DiMarco are infectious disease faculty members at the U...

9 Marras 202315min

Safe and Safer Supply for People Who Use Drugs

Safe and Safer Supply for People Who Use Drugs

The United States is in the midst of an overdose crisis that’s been exacerbated by the COVID-19 pandemic and increased toxicity of the drug supply, largely a result of adulterants like fentanyl and ot...

12 Loka 202332min

REPRIEVE: Pitavastatin to Prevent Cardiovascular Disease in HIV

REPRIEVE: Pitavastatin to Prevent Cardiovascular Disease in HIV

HIV patients are known to have up to a two-fold increase in heart-related events, compared with the general population. Could treatment with statins reduce this risk? Dr. Steven Fine, an infectious di...

14 Syys 202312min

Making a SPLASH! Long-acting Injectables for vulnerable populations with HIV

Making a SPLASH! Long-acting Injectables for vulnerable populations with HIV

The clinical innovation of antiretroviral treatment for HIV is a major public health victory that has transformed the shape of the epidemic. Healthcare professionals must remain committed to reaching ...

10 Elo 202318min

Tackling Syphilis: A Conversation with the New York State Department of Health AIDS Institute Office of Sexual Health and Epidemiology

Tackling Syphilis: A Conversation with the New York State Department of Health AIDS Institute Office of Sexual Health and Epidemiology

In this episode, Dr. Marguerite Urban chats with Drs. Rachel Hart-Malloy and Wilson Miranda from the New York State Department of Health AIDS Institute Office of Sexual Health and Epidemiology (OSHE) ...

13 Heinä 202330min

Integrating Hepatitis C Treatment into Opioid Treatment Programs: The Greenwich House Story

Integrating Hepatitis C Treatment into Opioid Treatment Programs: The Greenwich House Story

Hepatitis C virus (HCV) infection is a major public health problem responsible for substantial morbidity, including cirrhosis and liver cancer, and mortality. In 2021, over 6,500 new cases were report...

8 Kesä 202331min

Talking to patients about Lenacapavir (Sunlenca); the new long-acting injectable medication for HIV

Talking to patients about Lenacapavir (Sunlenca); the new long-acting injectable medication for HIV

In this episode, Dr. Steven Fine, an infectious disease specialist affiliated with the University of Rochester and Anthony Jordan Health Center explains the pros and cons behind the newly approved Len...

11 Touko 202316min

Suosittua kategoriassa Koulutus

rss-murhan-anatomia
psykopodiaa-podcast
voi-hyvin-meditaatiot-2
adhd-podi
psykologia
rss-valo-minussa-2
rss-tietoinen-yhteys-podcast-2
rss-rahamania
rss-niinku-asia-on
kesken
rss-arkea-ja-aurinkoa-podcast-espanjasta
rahapuhetta
rss-liian-kuuma-peruna
rss-narsisti
dear-ladies
rss-eron-alkemiaa
rss-vapaudu-voimaasi
leikitaanko-laakaria
aamukahvilla
rss-uskonto-on-tylsaa